Pitavastatin as the preferred statin for control of dyslipidemia in patients with HIV infection using antiretrovirals
Objective: explain why pitavastatin is the lipid-lowering agent of choice for lipid control and cardiovascular risk reduction in people infected with HIV. Methods: Searches were carried out inPubMed and the Virtual Health Library (VHL), using these descriptors, in English and Portuguese: “Pitavastat...
| Authors: | , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2023 |
| Country: | Brasil |
| Institution: | Faculdade de Medicina de Olinda (FMO) |
| Repository: | Anais da Faculdade de Medicina de Olinda (Online) |
| Language: | Portuguese English |
| OAI Identifier: | oai:ojs.afmo.emnuvens.com.br:article/279 |
| Online Access: | https://afmo.emnuvens.com.br/afmo/article/view/279 |
| Access Level: | Open access |
| Keyword: | Antirretrovirais HIV Hiperlipidemia Hipolipemiantes Estatinas Antiretrovirals Hyperlipidemia Hypolipidemic Statins |
| Summary: | Objective: explain why pitavastatin is the lipid-lowering agent of choice for lipid control and cardiovascular risk reduction in people infected with HIV. Methods: Searches were carried out inPubMed and the Virtual Health Library (VHL), using these descriptors, in English and Portuguese: “Pitavastatin”, “HIV”, “Statins”, “Infected by HIV”, “Dyslipidemia” and “Antiretrovirals”. 46 articles were retrieved, reduced, after refinement, to 9, 6 from PubMed and 3 from VHL. Results: The use of antiretrovirals (ARVs) significantly increases lipid alterations in HIV-infected people and should be associated with lipid-lowering therapy with statins. However, as most of them are metabolized by the cytochrome P450 3A4 system, which is inhibited by some ARVs, pitavastatin stands out, since its metabolization process occurs primarily by glucuronidation. Furthermore, it was provedthat this statin showed more inflammatory markers and LDL-c levels than pravastatin, which is metabolized through the same mechanism. Conclusion: Therefore, pitavastatin is preferably the lipid-lowering agent to correct dyslipidemia in HIV-infected patients, due to its minimal drug reactions and greater reduction in lipids and inflammatory markers. |
|---|